Arch Biopartners Inc.
ARCH.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.30K | -- | 84.20K | -264.40K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.30K | -- | 84.20K | -264.40K | -- |
| Cost of Revenue | 82.90K | 90.40K | 73.00K | 285.60K | 345.70K |
| Gross Profit | 31.30K | -90.40K | 11.20K | -550.00K | -345.70K |
| SG&A Expenses | 174.30K | 263.10K | 192.20K | 192.50K | 205.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 257.30K | 353.50K | 265.20K | 478.20K | 551.00K |
| Operating Income | -143.00K | -353.50K | -181.00K | -742.60K | -551.00K |
| Income Before Tax | -175.20K | -435.00K | -297.40K | -809.40K | -646.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.20K | -435.00K | -297.40K | -809.40K | -646.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.20K | -435.00K | -297.40K | -809.40K | -646.40K |
| EBIT | -143.00K | -353.50K | -181.00K | -742.60K | -551.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 66.11M | 65.47M | 64.94M | 60.77M | 62.76M |
| Average Diluted Shares Outstanding | 66.11M | 65.47M | 64.94M | 60.77M | 62.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |